Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
David StaskinJeffrey FrankelSusann VaranoMichael J KennellyDiane K NewmanMatt T RosenbergDenise D ShortinoRachael A JankowichPaul N MuddPublished in: International journal of clinical practice (2022)
In this subgroup analysis from the EMPOWUR trial, vibegron was associated with significant reductions compared with placebo in urgency episodes and micturitions in both the OAB dry and wet populations, suggesting that vibegron is similarly efficacious for these endpoints in patients with and without UUI. This trial is registered with NCT03492281.